Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis

Cancers (Basel). 2025 Jan 24;17(3):390. doi: 10.3390/cancers17030390.

Abstract

Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications [...].

Keywords: TNF-alpha; adalimumab; cancer; certolizumab; etanercept; golimumab; infliximab; meta-analysis.

Publication types

  • Review